ROS as a Novel Indicator to Predict Anticancer Drug Efficacy

Abstract

Background Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) generation. Generally, cancer cells with mitochondrial genetic abnormalities (copy number change and mutations) have escalated ROS levels compared to normal cells. Since high levels of ROS can trigger apoptosis, treating cancer cells with low doses of mitochondria-targeting / ROS-stimulating agents may offer cancer-specific therapy. This study aimed to investigate how baseline ROS levels might influence cancer cells’ response to ROS-stimulating therapy. Methods Four cancer and one normal cell lines were treated with a conventional drug (cisplatin) and a mitochondria-targeting agent (dequalinium chloride hydrate) separately and jointly. Cell viability was assessed and drug combination synergisms were indicated by the combination index (CI). Mitochondrial DNA copy number (MtDNAcn), ROS and mitochondrial membrane potential (MMP) were measured, and the relative expression levels of the genes and proteins involved in ROS-mediated apoptosis pathways were also investigated. Results Our data showed a correlation between the baseline ROS level, mtDNAcn and drug sensitivity in the tested cells. Synergistic effect of both drugs was also observed with ROS being the key contributor in cell death. Conclusions Our findings suggest that mitochondria-targeting therapy could be more effective compared to conventional treatments. In addition, cancer cells with low levels of ROS may be more sensitive to the treatment, while cells with high levels of ROS may be more resistant. This study provides an insight into understanding the influence of intracellular ROS on drug sensitivity, and may lead to the development of new therapeutic strategies to improve efficacy of anticancer therapy.

The impact of curcumin-graphene based nanoformulation on cellular interaction and redox-activated apoptosis: An in vitro colon cancer study

“…These results suggest both concentration and time-dependent, persistent oxidative stress state, and agree with CR pro-oxidant role as proved by previous reports using cancer cell models [23,81,82,83]. To this point, higher baseline ROS levels were observed in the control untreated SW-948 cell line compared to HT-29 counterpart, which may indicate the cellular built-in differences in genetic platforms as reported in literature [86,87,88]. Interestingly, CAG nanocomposite demonstrated ability to induce ROS production in both tested cell lines which further corroborate previous findings using plant-based flavonoids [89].…”

Polyphenolic Composition and Anti-Melanoma Activity of White Forsythia (Abeliophyllum distichum Nakai) Organ Extracts

“…Reactive oxygen species (ROS), generated through various extracellular and intracellular actions, function as very important intracellular messengers involved in the growth, differentiation, progression, metabolism, and death of cells [ 18 ]. In cancer cells, low doses of ROS promote cell proliferation in various cancer cell types, although excessive levels of ROS activate several signaling pathways involved in cell apoptosis [ 19 ].…”

Clinical Relevance and Tumor Growth Suppression of Mitochondrial ROS Regulators along NADH:Ubiquinone Oxidoreductase Subunit B3 in Thyroid Cancer

“…Generally, tumor cells have increased ROS levels compared with those normal cells [5]. As high ROS levels trigger apoptosis, treating cancer cells with doses of mitoROSsimulating agents may offer a cancer-specific therapy [5]. The effects of various kinds of antioxidants on tumor growth have yielded mixed results.…”